Inivata will host a session on liquid biopsy at PMWC January 23rd, 2017
We are excited to be hosting a session on liquid biopsy at the upcoming PMWC conference in Silicon Valley on January 23rd.
Learn more about our session on the Future of ctDNA here: http://www.pmwcintl.com/2…/sessionthemes-clinical-app-ctdna/
This session will include panelists Clive Morris, Inivata CMO; Nitzan Rosenfeld, Inivata CSO; and Ramaswamy Govindan, Director of Medical Oncology at Washington University. You can view a Question & Answer session with our CMO, Clive Morris and PMWC here: http://www.pmwcintl.com/2017sv/clive-morris-qa/
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.